Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas

被引:11
作者
Bossard, Celine [1 ]
Kuery, Sebastien [1 ]
Jamet, Philippe [2 ,3 ]
Senellart, Helene [4 ]
Airaud, Fabrice [1 ]
Ramee, Jean-Francois [5 ]
Bezieau, Stephane [1 ]
Matysiak-Budnik, Tamara [1 ,2 ,3 ]
Laboisse, Christian L. [1 ]
Mosnier, Jean-Francois [1 ]
机构
[1] Univ Nantes, Fac Med Nantes, EA Biometadys 4273, F-44035 Nantes, France
[2] CHU Nantes, Inst Malad Appareil Digestif, Nantes, France
[3] CHU Nantes, Serv Hepatogastroenterol, Nantes, France
[4] Ctr Lutte Canc Nantes Atlantique, Med Oncol Serv, Nantes, France
[5] Ctr Catherine Sienne, Med Oncol Serv, Nantes, France
关键词
K-RAS MUTATIONS; HETEROGENEITY; CETUXIMAB; CARCINOMAS; BENEFIT; TUMORS;
D O I
10.1136/jclinpath-2011-200608
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study addresses the extent of the heterogeneity of KRAS status, present in a minority of metastatic colorectal carcinomas (mCRCs), on the basis of a thorough analysis of surgical resection specimens. Eighteen patients with mCRC were included. KRAS mutations (exon 2, codons 12 and 13) were determined using PCR and subsequent direct sequencing. This analysis included primary tumours (n = 21), synchronous (n = 10) and metachronous (n = 18) matched metastases, and pelvic recurrence (n = 1). Heterogeneity of KRAS status consisted in KRAS mutated in (i) the primary tumour but not in its synchronous metastasis, (ii) the metastasis but not in the primary tumour, (iii) the pelvic recurrence but not in the primary tumour, (iiii) some metastases and not in others from the same patient. Finally, the KRAS status varied among different areas of the same metastatic focus. This study defines the concept of KRAS mosaicism that affects a minority of mCRCs.
引用
收藏
页码:466 / 469
页数:4
相关论文
共 13 条
[1]  
Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO
[2]  
2-M
[3]   Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations [J].
Albanese, I ;
Scibetta, AG ;
Migliavacca, M ;
Russo, A ;
Bazan, V ;
Tomasino, RM ;
Colomba, P ;
Tagliavia, M ;
La Farina, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 325 (03) :784-791
[4]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[5]   Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].
Baldus, Stephan E. ;
Schaefer, Karl-L. ;
Engers, Rainer ;
Hartleb, Dinah ;
Stoecklein, Nikolas H. ;
Gabbert, Helmut E. .
CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799
[6]   K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy [J].
Etienne-Grimaldi, Marie-Christine ;
Formento, Jean-Louis ;
Francoual, Mireille ;
Francois, Eric ;
Formento, Patricia ;
Renee, Nicole ;
Laurent-Puig, Pierre ;
Chazal, Maurice ;
Benchimol, Daniel ;
Delpero, Jean-Robert ;
Letoublon, Christian ;
Pezet, Denis ;
Seitz, Jean-Frangois ;
Milano, Gerard .
CLINICAL CANCER RESEARCH, 2008, 14 (15) :4830-4835
[7]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[8]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[9]   Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls [J].
Lamy, Aude ;
Blanchard, France ;
Le Pessot, Florence ;
Sesbouee, Richard ;
Di Fiore, Frederic ;
Bossut, Jessie ;
Fiant, Elodie ;
Frebourg, Thierry ;
Sabourin, Jean-Christophe .
MODERN PATHOLOGY, 2011, 24 (08) :1090-1100
[10]   KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].
Lièvre, A ;
Bachet, JB ;
Le Corre, D ;
Boige, V ;
Landi, B ;
Emile, JF ;
Côté, JF ;
Tomasic, G ;
Penna, C ;
Ducreux, M ;
Rougier, P ;
Penault-Llorca, F ;
Laurent-Puig, P .
CANCER RESEARCH, 2006, 66 (08) :3992-3995